Hypertension in Pregnancy among HIV-Infected Women in Sub-Saharan Africa: Prevalence and Infant Outcomes

C Kilewo, UCM Natchu, A Young, D Donnell, E Brown, JS Read, U Sharma, BH Chi, R Goldenberg, I Hoffman, TE Taha, WW Fawzi


This analysis was performed to determine the prevalence of hypertension and association of MAP (mean arterial pressure) with birth outcomes among HIV-infected pregnant women not taking antiretrovirals. HIV-infected pregnant women, enrolled into the HPTN024 trial in Tanzania, Malawi and Zambia were followed up at 26-30, 36 weeks, and delivery. The prevalence of hypertension was <1% at both 20-24 weeks and 26-30 weeks and 1.7% by 36 weeks. A 5 mm Hg elevation in MAP increased the risk of stillbirth at 20-24 weeks by 29% (p=0.001), 32% (p=0.001) at 26-30 weeks and of low birth weight (LBW) at 36 weeks by 26% (p=0.001). MAP was not associated with stillbirth at 36 weeks, LBW prior to 36 weeks, preterm birth, neonatal mortality or the risk of maternal to child transmission (MTCT) of HIV  (Afr J Reprod Health 2009; 13[4]:25-36).



L’hypertension pendant la grossesse chez les femmes séropositives en Afrique subsaharienne : Prévalence et les résultats infantiles. On a fait cette analyse pour déterminer la prévalence de l’hypertension et l’association de la PAM (Pression Artérielle Moyenne) avec les résultats de naissance chez les femmes séropositives enceintes qui ne prennent pas des médicaments antirétroviraux.  Les femmes séropositives enceintes inscrites pour l’essai PHTNO24 en Tanzanie, au Malawi et en Zambie ont été suivies à 26 – 30, 36 semaines et à l’accouchement.  La prévalence de l’hypertension était <1% à la fin de 20 – 24 semaines et à la fin de 26 – 30 semaines et 1,7% à la fin de 36 semaines.  Une hausse de 5mm Hg de la PAM a augmente le risque de la mortinatalité à la fin de 20 – 24 semaines de 29% (p = 0,001), 32% (p = 0,001) à la fin de 26 – 30 semaines et de la faible poids de naissance (FPN) à la fin de 36 semaines de 26% (p = 0,001).  La PAM n’était pas liée à la mortinatalité à la fin de 36 semaines, à la FPN avant 36 semaines, à la naissance avant-terme, à la mortalité néonatale ou au risque de la transmission de la mère à l’enfant (TME) du VIH  (Afr J Reprod Health 2009; 13[4]:25-36).




KEYWORDS: Perinatal mortality, hypertension, Africa, stillbirth, low birth weight, mean arterial pressure, pregnancy

Full Text:



Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX–XIV.

WHO study group. Hypertensive disorders of pregnancy. Technical report Series No. 758 Geneva: World Health Organization 1987: 14-5.

Paller MS. Hypertension in pregnancy. J Am Soc Nephrol. 1998 Feb;9(2):314-21.

Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367(9516):1066-74.

Urassa DP, Nystrom L, Carlstedt A et al. Management of hypertension in pregnancy as a quality Indicator of antenatal care in rural Tanzania. Afr J Reprod Hlth 2003; 7 (3): 69 – 76.

Majoko F, Nystrom L, Munjanja SP, et al. Relation of parity to pregnancy outcome in a rural community in Zimbabwe. Afr J Reprod Hlth 2004; 8 (3): 198 – 206.

de Ruiter A, Brocklehurst P. HIV infection and pregnancy. Int J STD AIDS. 1998; 9(11):647-54.

Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 1998; 105:836- 48.

Wimalasundera RC, Larbalestier N, Smith JH, de Ruiter A, McG Thom SA, Hughes AD, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002; 360:1152– 4.

Trumbo PR, Ellwood KC. Supplemental calcium and risk reduction of hypertension, pregnancy-induced hypertension, and preeclampsia: an evidence-based review by the US Food and Drug Administration. Nutr Rev. 2007; 65(2):78-87.

Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol 2003; 101: 1319 –1332.

Chappell LC, Seed PT, Kelly FJ, Briley A, Hunt BJ, Charnock-Jones DS, Mallet A, Poston L. Vitamin C and E supplementation in women at risk of preeclampsia is associated with changes in indices of oxidative stress and placental function. Am J Obstet Gynecol 2002; 187: 777–784.

Merchant AT, Msamanga G, Villamor E, Saathoff E, O’Brien M, Hertzmark E,

Hunter DJ, and Fawzi WW. Multivitamin Supplementation of HIV-Positive Women during Pregnancy Reduces Hypertension. J Nut 2005; 135(7):1776-81.

Page EW, Christianson R. The impact of mean arterial pressure (MAP) in the middle trimester upon the outcome of pregnancy. Am J Obstet Gynecol 1976;125:749.

Ebeigbe PN, Gharoro EP. A raised midtrimester mean arterial blood pressure: is it predictive of pregnancy induced hypertension in Nigerian pregnant women? Niger Postgrad Med J. 2004 Dec;11(4):294-

Conde-Agudelo A, Belizan JM, Lede R, Bergel EF. What does an elevated mean arterial pressure in the second half of pregnancy predict--gestational hypertension or preeclampsia? Am J Obstet Gynecol. 1993;169(3):509-14.

Taha TE, Brown ER, Hoffman IF, Fawzi W, Read JS, et al. A phase II clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 tranmission. AIDS 2006; 20(9): 1213–21.

Goldenberg RL, Mwatha A, Read JS, Adeniyi-Jones S, Sinkala M, Msmanga G, Martinson F, Hoffman I, Fawzi W, Valentine M, Emel L, Brown E, Mudenda V, Taha TE; HPTN024 Team. The HPTN 024 Study: the efficacy of antibiotics to prevent chorioamnionitis and preterm birth. Am J Obstet Gynecol 2006;194(3):650-61.

Geographic variation in the incidence of hypertension in pregnancy. World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Am J Obstet Gynecol.


Naidoo DV, Moodley J. A survey of hypertension in pregnancy at the King Edward VIII Hospital, Durban. S Afr Med J. 1980 Oct 4;58(14):556-9.

Chen XK, Wen SW, Smith G, Leader A, Sutandara M, Yang Q, Walker M. Maternal age, paternal age and new-onset hypertension in late pregnancy. Hypertens Pregnancy. 2006;25(3):217-27.

Marai W, Lakew Z. Pregnancy outcome in the elderly gravida in Addis Ababa. East Afr Med J. 2002;79(1):34-7.

Mahomed K, Williams MA, Woelk GB, Jenkins-Woelk L, Mudzamiri S, Longstaff L, Sorensen TK. Risk factors for pre-eclampsia among Zimbabwean women: maternal arm circumference and other anthropometric measures of obesity. Paediatr Perinat Epidemiol. 1998 Jul;12(3):253-62.

Lang U, Baker RS, Braems G, Zygmunt M, Kunzel W, Clark KE. Uterine blood flow--a determinant of fetal growth. Eur J Obstet Gynecol Reprod Biol. 2003;110 Suppl 1:S55-61.

Bergersen BM. Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. Drugs.


Suy A, Esteban M, Oriol C et al. Increased risk of pre-eclampsia and fetal death in HIV infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006;20:59-66.


  • There are currently no refbacks.